# EDGAR Filing Document

**Accession Number:** 0001673985
**File Stem:** 0001673985-25-000119
**Filing Date:** 2025-8
**Character Count:** 135562
**Document Hash:** 7598b12df59acae95185ecf340af4012
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001673985-25-000119.hdr.sgml**: 20250801

**ACCESSION NUMBER**: 0001673985-25-000119

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 67

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250801

**DATE AS OF CHANGE**: 20250801

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AdvanSix Inc.
- **CENTRAL INDEX KEY:** 0001673985
- **STANDARD INDUSTRIAL CLASSIFICATION:** PLASTICS, MATERIALS, SYNTH RESINS & NONVULCAN ELASTOMERS [2821]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 812525089
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37774
- **FILM NUMBER:** 251176298

**BUSINESS ADDRESS:**
- **STREET 1:** 300 KIMBALL DRIVE
- **STREET 2:** SUITE 101
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054
- **BUSINESS PHONE:** (973) 526-1800

**MAIL ADDRESS:**
- **STREET 1:** 300 KIMBALL DRIVE
- **STREET 2:** SUITE 101
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054

?xml version='1.0' encoding='ASCII'? asix-20250630

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

---

| | |
|:---|:---|
| (Mark One) | (Mark One) |
| ☒ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

 **For the quarterly period ended June 30, 2025** 

or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _____ to _____**

**Commission File Number: 1-37774**

---

| |
|:---|
| **AdvanSix Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Delaware** | **81-2525089** |
| *(State or other jurisdiction of*<br>*incorporation or organization)* | *(I.R.S. Employer Identification No.)* |

---

---

| | |
|:---|:---|
| **300 Kimball Drive, Suite 101, Parsippany, New Jersey** | **07054** |
| *(Address of principal executive offices)* | *(Zip Code)* |

---

**(973) 526-1800**

*(Registrant's telephone number, including area code)*

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | ASIX | New York Stock Exchange |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes 🗷 No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes 🗷 No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer 🗷 Accelerated filer □ Non-accelerated filer □ Smaller reporting company ☐ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No 🗷

The Registrant had 26,844,187 shares of common stock, $0.01 par value, outstanding at July 25, 2025.

------

**ADVANSIX INC.** 

**FORM 10-Q**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| <u>[Part I.](#i0b2d07fcda20427c9a24ccf3966539e9_10)</u> | <u>[FINANCIAL INFORMATION](#i0b2d07fcda20427c9a24ccf3966539e9_10)</u> | |
| <u>[Item 1.](#i0b2d07fcda20427c9a24ccf3966539e9_13)</u> | <u>[Financial Statements](#i0b2d07fcda20427c9a24ccf3966539e9_13)</u> | <u>[3](#i0b2d07fcda20427c9a24ccf3966539e9_16)</u> |
| | <u>[Condensed Consolidated Statements of Operations for the](#i0b2d07fcda20427c9a24ccf3966539e9_16)three and six months ended June 30, 2025 and 2024(unaudited)</u> | <u>[3](#i0b2d07fcda20427c9a24ccf3966539e9_16)</u> |
| | <u>[Condensed Consolidated Statements of Comprehensive Income](#i0b2d07fcda20427c9a24ccf3966539e9_19)[for the](#i0b2d07fcda20427c9a24ccf3966539e9_19)three and six months ended June 30, 2025 and 2024[(unaudited)](#i0b2d07fcda20427c9a24ccf3966539e9_19)</u> | <u>[4](#i0b2d07fcda20427c9a24ccf3966539e9_19)</u> |
| | <u>[Condensed Consolidated Balance Sheets as of](#i0b2d07fcda20427c9a24ccf3966539e9_22)June 30, 2025[and](#i0b2d07fcda20427c9a24ccf3966539e9_22)December 31, 2024[(unaudited)](#i0b2d07fcda20427c9a24ccf3966539e9_22)</u> | <u>[5](#i0b2d07fcda20427c9a24ccf3966539e9_22)</u> |
| | <u>[Condensed Consolidated Statements of Cash Flows for the](#i0b2d07fcda20427c9a24ccf3966539e9_25)six months ended June 30, 2025 and 2024[(unaudited)](#i0b2d07fcda20427c9a24ccf3966539e9_25)</u> | <u>[6](#i0b2d07fcda20427c9a24ccf3966539e9_25)</u> |
| | <u>[Condensed Consolidated Statements of Stockholders' Equity for the](#i0b2d07fcda20427c9a24ccf3966539e9_28)three and six months ended June 30, 2025 and 2024[(unaudited)](#i0b2d07fcda20427c9a24ccf3966539e9_28)</u> | <u>[7](#i0b2d07fcda20427c9a24ccf3966539e9_28)</u> |
| | <u>[Notes to Condensed Consolidated Financial Statements (unaudited)](#i0b2d07fcda20427c9a24ccf3966539e9_31)</u> | <u>[9](#i0b2d07fcda20427c9a24ccf3966539e9_31)</u> |
| <u>[Item 2.](#i0b2d07fcda20427c9a24ccf3966539e9_100)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i0b2d07fcda20427c9a24ccf3966539e9_100)</u> | <u>[17](#i0b2d07fcda20427c9a24ccf3966539e9_100)</u> |
| <u>[Item 3.](#i0b2d07fcda20427c9a24ccf3966539e9_157)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i0b2d07fcda20427c9a24ccf3966539e9_157)</u> | <u>[26](#i0b2d07fcda20427c9a24ccf3966539e9_157)</u> |
| <u>[Item 4.](#i0b2d07fcda20427c9a24ccf3966539e9_160)</u> | <u>[Controls and Procedures](#i0b2d07fcda20427c9a24ccf3966539e9_160)</u> | <u>[27](#i0b2d07fcda20427c9a24ccf3966539e9_160)</u> |
| <u>[Part II.](#i0b2d07fcda20427c9a24ccf3966539e9_163)</u> | <u>[OTHER INFORMATION](#i0b2d07fcda20427c9a24ccf3966539e9_163)</u> | <u>[27](#i0b2d07fcda20427c9a24ccf3966539e9_163)</u> |
| <u>[Item 1.](#i0b2d07fcda20427c9a24ccf3966539e9_166)</u> | <u>[Legal Proceedings](#i0b2d07fcda20427c9a24ccf3966539e9_166)</u> | <u>[27](#i0b2d07fcda20427c9a24ccf3966539e9_166)</u> |
| <u>[Item 1A.](#i0b2d07fcda20427c9a24ccf3966539e9_169)</u> | <u>[Risk Factors](#i0b2d07fcda20427c9a24ccf3966539e9_169)</u> | <u>[27](#i0b2d07fcda20427c9a24ccf3966539e9_169)</u> |
| <u>[Item 2.](#i0b2d07fcda20427c9a24ccf3966539e9_172)</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i0b2d07fcda20427c9a24ccf3966539e9_172)</u> | <u>[27](#i0b2d07fcda20427c9a24ccf3966539e9_172)</u> |
| <u>[Item 5.](#i0b2d07fcda20427c9a24ccf3966539e9_175)</u> | <u>[Other Information](#i0b2d07fcda20427c9a24ccf3966539e9_175)</u> | <u>[28](#i0b2d07fcda20427c9a24ccf3966539e9_175)</u> |
| <u>[Item 6.](#i0b2d07fcda20427c9a24ccf3966539e9_181)</u> | <u>[Exhibits](#i0b2d07fcda20427c9a24ccf3966539e9_181)</u> | <u>[29](#i0b2d07fcda20427c9a24ccf3966539e9_181)</u> |
| | <u>[Signature](#i0b2d07fcda20427c9a24ccf3966539e9_184)</u> | <u>[30](#i0b2d07fcda20427c9a24ccf3966539e9_184)</u> |

---

------

**PART I. FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Unaudited)**

**(Dollars in thousands, except share and per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Sales | $410022 | $453479 | $787813 | $790308 |
| Costs, expenses and other: |  |  |  |  |
| &nbsp;&nbsp;Costs of goods sold | 351308 | 372111 | 675628 | 705975 |
| &nbsp;&nbsp;Selling, general and administrative expenses | 25416 | 24431 | 48825 | 48024 |
| &nbsp;&nbsp;Interest expense, net | 2255 | 3514 | 3796 | 6213 |
| &nbsp;&nbsp;Other non-operating (income) expense, net | (607) | 1351 | (1015) | 1441 |
| Total costs, expenses and other | 378372 | 401407 | 727234 | 761653 |
| Income before taxes | 31650 | 52072 | 60579 | 28655 |
| Income tax expense | 279 | 13145 | 5864 | 7124 |
| Net income | $31371 | $38927 | $54715 | $21531 |
| Earnings per common share |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $1.17 | $1.45 | $2.04 | $0.80 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $1.15 | $1.43 | $2.01 | $0.79 |
| Weighted average common shares outstanding |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 26896037 | 26839429 | 26867252 | 26859044 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 27223309 | 27150347 | 27248976 | 27251326 |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

**(Unaudited)**

**(Dollars in thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income | $31371 | $38927 | $54715 | $21531 |
| Foreign exchange translation adjustment | 24 | (27) | 35 | (42) |
| Cash-flow hedges |  |  | 7 | 7 |
| Other comprehensive income (loss), net of tax | 24 | (27) | 42 | (35) |
| Comprehensive income | $31395 | $38900 | $54757 | $21496 |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(Unaudited)**

**(Dollars in thousands, except share and per share amounts)**

---

| | | |
|:---|:---|:---|
| | **June 30,<br>2025** | **December 31,<br>2024** |
| **ASSETS** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $18446 | $19564 |
| &nbsp;&nbsp;Accounts and other receivables – net | 159702 | 145673 |
| &nbsp;&nbsp;Inventories – net | 221764 | 212386 |
| &nbsp;&nbsp;Taxes receivable | 15243 | 503 |
| &nbsp;&nbsp;Other current assets | 19021 | 8990 |
| Total current assets | 434176 | 387116 |
| Property, plant and equipment – net | 936309 | 917858 |
| Operating lease right-of-use assets | 136888 | 153438 |
| Goodwill | 56192 | 56192 |
| Intangible assets | 41619 | 43144 |
| Other assets | 41218 | 37172 |
| Total assets | $1646402 | $1594920 |
| **LIABILITIES** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $231907 | $228761 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 48200 | 47264 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 384 | 1047 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities – short-term | 38718 | 42493 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income and customer advances | 1858 | 37538 |
| Total current liabilities | 321067 | 357103 |
| Deferred income taxes | 151938 | 145299 |
| Operating lease liabilities – long-term | 99037 | 111400 |
| Line of credit – long-term | 240000 | 195000 |
| Other liabilities | 10628 | 11468 |
| Total liabilities | 822670 | 820270 |
| **COMMITMENTS AND CONTINGENCIES (Note 9)** |  |  |
| **STOCKHOLDERS' EQUITY** |  |  |
| Common stock, par value $0.01; 200,000,000 shares authorized; 33,152,286 shares issued and 26,844,187 outstanding at June 30, 2025; 32,989,165 shares issued and 26,737,036 outstanding at December 31, 2024 | 332 | 330 |
| Preferred stock, par value $0.01; 50,000,000 shares authorized and 0 shares issued and outstanding at June 30, 2025 and December 31, 2024 |  |  |
| Treasury stock at par (6,308,099 shares at June 30, 2025; 6,252,129 shares at December 31, 2024) | (63) | (63) |
| Additional paid-in capital | 140097 | 136872 |
| Retained earnings | 677354 | 631541 |
| Accumulated other comprehensive income | 6012 | 5970 |
| Total stockholders' equity | 823732 | 774650 |
| Total liabilities and stockholders' equity | $1646402 | $1594920 |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

**(Dollars in thousands)**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| Net income | $54715 | $21531 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 38639 | 38264 |
| &nbsp;&nbsp;(Gain) loss on disposal of assets | (177) | 261 |
| &nbsp;&nbsp;Deferred income taxes | 6646 | 751 |
| &nbsp;&nbsp;Stock-based compensation | 4287 | 4404 |
| &nbsp;&nbsp;Amortization of deferred financing fees | 309 | 309 |
| &nbsp;&nbsp;Operational asset adjustments |  | 1200 |
| &nbsp;&nbsp;Changes in assets and liabilities, net of business acquisitions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and other receivables | (13994) | (6004) |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | (9378) | 36004 |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes receivable | (14740) | 1255 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 12423 | (61681) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | (663) | (7026) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 561 | 6149 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income and customer advances | (35680) | (14530) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | (10395) | (6889) |
| Net cash provided by operating activities | 32553 | 13998 |
| **Cash flows from investing activities:** |  |  |
| Expenditures for property, plant and equipment | (62327) | (68883) |
| Other investing activities | (5891) | (3736) |
| Net cash used for investing activities | (68218) | (72619) |
| **Cash flows from financing activities:** |  |  |
| Borrowings from line of credit | 231500 | 257500 |
| Repayments of line of credit | (186500) | (197500) |
| Principal payments of finance leases | (491) | (502) |
| Dividend payments | (8580) | (8582) |
| Purchase of treasury stock | (1537) | (10385) |
| Issuance of common stock | 155 | 427 |
| Net cash provided by financing activities | 34547 | 40958 |
| Net change in cash and cash equivalents | (1118) | (17663) |
| Cash and cash equivalents at beginning of period | 19564 | 29768 |
| Cash and cash equivalents at the end of period | $18446 | $12105 |
| Supplemental non-cash investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures included in accounts payable | $14762 | $14932 |
| Supplemental cash activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $2297 | $6015 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes | $15080 | $13587 |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(Unaudited)**

**(Dollars in thousands)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| | **Shares** | **Amount** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| **Balance at December 31, 2024** | 32989165 | $330 | $136872 | $631541 | $(63) | $5970 | $774650 |
| Net income |  |  |  | 23344 |  |  | 23344 |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | 11 | 11 |
| &nbsp;&nbsp;Cash-flow hedges |  |  |  |  |  | 7 | 7 |
| Other comprehensive income, net of tax |  |  |  |  |  | 18 | 18 |
| Issuance of common stock | 124214 | 1 | 153 |  |  |  | 154 |
| Purchase of treasury stock (53,432 shares) |  |  | (1486) |  |  |  | (1486) |
| Stock-based compensation |  |  | 1978 |  |  |  | 1978 |
| Dividends |  |  | 160 | (4450) |  |  | (4290) |
| **Balance at March 31, 2025** | **33113379** | **331** | **137677** | **650435** | **(63)** | **5988** | **794368** |
| Net income |  |  |  | 31371 |  |  | 31371 |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | 24 | 24 |
| Other comprehensive loss, net of tax |  |  |  |  |  | 24 | 24 |
| Issuance of common stock | 38907 | 1 |  |  |  |  | 1 |
| Purchase of treasury stock (2,538 shares) |  |  | (51) |  |  |  | (51) |
| Stock-based compensation |  |  | 2309 |  |  |  | 2309 |
| Dividends |  |  | 162 | (4452) |  |  | (4290) |
| **Balance at June 30, 2025** | **33152286** | $**332** | $**140097** | $**677354** | $**(63)** | $**6012** | $**823732** |

---

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(Unaudited)**

**(Dollars in thousands)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| | **Shares** | **Amount** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| **Balance at December 31, 2023** | 32598946 | $326 | $138046 | $605067 | $(58) | $(4144) | $739237 |
| Net loss |  |  |  | (17396) |  |  | (17396) |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | (15) | (15) |
| &nbsp;&nbsp;Cash-flow hedges |  |  |  |  |  | 7 | 7 |
| Other comprehensive loss, net of tax |  |  |  |  |  | (8) | (8) |
| Issuance of common stock | 323989 | 3 | 423 |  |  |  | 426 |
| Purchase of treasury stock (260,464 shares) |  |  | (7020) |  | (3) |  | (7023) |
| Stock-based compensation |  |  | 2211 |  |  |  | 2211 |
| Dividends |  |  | 163 | (4453) |  |  | (4290) |
| **Balance at March 31, 2024** | **32922935** | **329** | **133823** | **583218** | **(61)** | **(4152)** | **713157** |
| Net income |  |  |  | 38927 |  |  | 38927 |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | (27) | (27) |
| Other comprehensive loss, net of tax |  |  |  |  |  | (27) | (27) |
| Issuance of common stock | 36653 | 1 |  |  |  |  | 1 |
| Purchase of treasury stock (141,242 shares) |  |  | (3360) |  | (2) |  | (3362) |
| Stock-based compensation |  |  | 2193 |  |  |  | 2193 |
| Dividends |  |  | 130 | (4422) |  |  | (4292) |
| **Balance at June 30, 2024** | **32959588** | $**330** | $**132786** | $**617723** | $**(63)** | $**(4179)** | $**746597** |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

**1. Organization, Operations and Basis of Presentation**

***Description of Business***

AdvanSix Inc. ("AdvanSix," the "Company," "we" or "our") is a diversified chemistry company that produces essential materials for our customers in a wide variety of end markets and applications that touch people's lives. Our integrated value chain of our five U.S.-based manufacturing facilities plays a critical role in global supply chains and enables us to innovate and deliver essential products for our customers across building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, electronics and other end markets. Guided by our core values of Safety, Integrity, Accountability and Respect, AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, plant nutrients, and chemical intermediates.

***Basis of Presentation***

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of June 30, 2025, and its results of operations for the three and six months ended June 30, 2025 and 2024 and cash flows for the six months ended June 30, 2025 and 2024. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year. These financial statements should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2024. All intercompany transactions have been eliminated.

Certain prior period amounts have been reclassified for consistency with the current period presentation.

It is our practice to establish actual quarterly closing dates using a predetermined fiscal calendar, which requires our businesses to close their books on a Saturday in order to minimize the potentially disruptive effects of quarterly closing on our business processes. Historically, the effects of this practice have generally not been significant to reported results for any quarter and only existed within a reporting year. In the event that differences in actual closing dates are material to year-over-year comparisons of quarterly or year-to-date results, we will provide the appropriate disclosures. Our actual closing dates for the three and six months ended June 30, 2025 and 2024 were June 28, 2025 and June 29, 2024, respectively.

Liabilities to creditors to whom we have issued checks that remained outstanding at June 30, 2025 and December 31, 2024 aggregated to $6.0 million and $7.3 million, respectively. These were included in Cash and cash equivalents and Accounts payable in the Condensed Consolidated Balance Sheets.

The Company previously reported a business impact associated with the June 2019 fire that shut down the Philadelphia Energy Solutions refinery in Philadelphia, Pennsylvania. The Company actively pursued a business interruption claim and reached a final omnibus settlement in January 2025 which resulted in insurance settlement proceeds of approximately $26 million in the first quarter of 2025. The total aggregate insurance proceeds since the original claim submission are approximately $39 million. The proceeds have been recognized as a reduction to Costs of Goods Sold on the Condensed Consolidated Statements of Operations in the periods in which they were received.

On February 17, 2023, the Company's Board of Directors (the "Board") authorized a share repurchase program to repurchase shares of the Company's common stock. As of June 30, 2025, the Company has repurchased a total of 6,308,099 shares of common stock, including 1,062,643 shares withheld to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $194.0 million at a weighted average market price of $30.75 per share. As of June 30, 2025, approximately $62.0 million remained available for share repurchases under the current authorization. During the period July 1, 2025 through July 25, 2025, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including through the use of trading plans intended to qualify under Rule

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.

**2. Recent Accounting Pronouncements**

**Recent Accounting Pronouncements** – The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued by the Financial Accounting Standards Board ("FASB"). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in this ASU require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses. The amendments require that at each interim and annual reporting period an entity will: (1) disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and (e) depreciation, depletion, and amortization recognized as part of oil-and gas-producing activities (or other amounts of depletion expense) included in each relevant expense caption. A relevant expense caption is an expense caption presented on the face of the income statement within continuing operations that contains any of the expense categories listed in (a)-(e); (2) include certain amounts that are already required to be disclosed under current generally accepted accounting principles (GAAP) in the same disclosure as other disaggregation requirements; (3) disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) disclose the total amount of selling expense and, in annual reporting periods, an entity's definition of selling expense. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendments in this ASU should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the pronouncement and does not expect adoption to have a material impact on the Company's consolidated financial position or results of operations.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this ASU require that public business entities, on an annual basis, disclose specific categories in the rate reconciliation and provide additional information for reconciling items that are equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. The amendments also require that the Company disclose the following (net of refunds received): (1) the amount of income taxes paid disaggregated by federal (national), state, and foreign taxes and (2) the amount of income taxes paid disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5 percent of total income taxes paid. Additionally, the amendments in this update eliminate the requirement for all entities to disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12 months or to make a statement that an estimate of the range cannot be made, and remove the requirement to disclose the cumulative amount of each type of temporary difference when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries and corporate joint ventures. This pronouncement is effective for annual periods beginning after December 31, 2024 and the required disclosures will be adopted in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

**3. Revenues**

***Revenue Recognition***

AdvanSix serves around 400 customers annually, primarily in the United States, spanning a wide variety of industries worldwide. For the six months ended June 30, 2025 and 2024, the Company's ten largest customers accounted for approximately 39% and 38% of total sales, respectively.

We typically sell to customers under master service agreements, with primarily one-year terms, or by purchase orders. We have historically experienced low customer turnover and have long-standing customer relationships, which span decades. Our largest customer is Shaw Industries Group, Inc. ("Shaw"), a significant consumer of caprolactam and Nylon 6 resin, to whom we sell under a long-term agreement. For each of the three months ended June 30, 2025 and 2024, the Company's sales to Shaw were 9% of our total sales.

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

The Company's revenue by product line, and related approximate percentage of total sales, for the three and six months ended June 30, 2025 and 2024 were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2025** | **2024\*** | **2024\*** | **2025** | **2025** | **2024\*** | **2024\*** |
| Nylon | $79503 | 20% | $103217 | 23% | $167871 | 21% | $187606 | 24% |
| Caprolactam | 66424 | 16% | 81303 | 18% | 133856 | 17% | 142779 | 18% |
| Plant Nutrients | 156770 | 38% | 147339 | 32% | 285011 | 36% | 242035 | 30% |
| Chemical Intermediates | 107325 | 26% | 121620 | 27% | 201075 | 26% | 217888 | 28% |
| Total | $410022 | 100% | $453479 | 100% | $787813 | 100% | $790308 | 100% |

---

*\* The Company transferred certain products between its Chemical Intermediates product line and its Plant Nutrients product line to align more closely with its current sales structure. Historical information has been reclassified to reflect these changes for all periods presented in the Consolidated Financial Statements. Total revenue amounts were not impacted for either period.*

The Company's revenues by geographic area, and related approximate percentage of total sales, for the three and six months ended June 30, 2025 and 2024 were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| United States | $358671 | 87% | $401859 | 89% | $679118 | 86% | $686447 | 87% |
| International \* | 51351 | 13% | 51620 | 11% | 108695 | 14% | 103861 | 13% |
| Total | $410022 | 100% | $453479 | 100% | $787813 | 100% | $790308 | 100% |

---

*\* Predominantly Latin America and Canada*

***Deferred Income and Customer Advances***

The Company defers revenues when cash payments are received in advance of our performance. Below is a roll-forward of Deferred income and customer advances for the six months ended June 30, 2025:

---

| | |
|:---|:---|
| Opening balance January 1, 2025 | $37538 |
| Additional cash advances |  |
| Less amounts recognized in revenues | (35680) |
| Ending balance June 30, 2025 | $1858 |

---

The Company expects to recognize as revenue the June 30, 2025 ending balance of Deferred income and customer advances within one year or less.

**4. Earnings Per Share**

The computation of basic and diluted earnings per share ("EPS") is based on Net income (loss) divided by the basic weighted average number of common shares outstanding and diluted weighted average number of common shares outstanding, respectively. The details of the basic and diluted EPS calculations for the three and six months ended June 30, 2025 and 2024 were as follows:

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Basic** |  |  |  |  |
| Net income | $31371 | $38927 | $54715 | $21531 |
| Weighted average common shares outstanding | 26896037 | 26839429 | 26867252 | 26859044 |
| EPS – Basic | $1.17 | $1.45 | $2.04 | $0.80 |
| **Diluted** |  |  |  |  |
| Dilutive effect of equity awards and other stock-based holdings | 327272 | 310918 | 381724 | 392282 |
| Weighted average common shares outstanding | 27223309 | 27150347 | 27248976 | 27251326 |
| EPS – Diluted | $1.15 | $1.43 | $2.01 | $0.79 |

---

Diluted EPS is computed based upon the weighted average number of common shares outstanding for the period plus the dilutive effect of common stock equivalents using the treasury stock method and the average market price of our common stock for the period.

The diluted EPS calculations exclude the effect of stock options when the options' assumed proceeds exceed the average market price of the common shares during the period. The anti-dilutive common stock equivalents outstanding at the three and six months ended June 30, 2025 and 2024 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Options and stock equivalents | 1005749 | 1057349 | 948963 | 1127661 |

---

Dividend activity for the three and six months ended June 30, 2025 and 2024 was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Cash dividends declared per share | $0.16 | $0.16 | $0.32 | $0.32 |
| Aggregate dividends paid to shareholders | $4290 | $4292 | $8580 | $8582 |

---

**5. Accounts and Other Receivables** – **Net**

---

| | | |
|:---|:---|:---|
| | **June 30,<br>2025** | **December 31,<br>2024** |
| Accounts receivables | $155701 | $141273 |
| Other | 4343 | 4982 |
| Total accounts and other receivables | 160044 | 146255 |
| Less – allowance for credit losses | (342) | (582) |
| Total accounts and other receivables – net | $159702 | $145673 |

---

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

**6. Inventories**

---

| | | |
|:---|:---|:---|
| | **June 30,<br>2025** | **December 31,<br>2024** |
| Raw materials | $103110 | $99320 |
| Work in progress | 92241 | 71175 |
| Finished goods | 73938 | 73994 |
| Spares and other | 32605 | 31948 |
|  | 301894 | 276437 |
| Reduction to LIFO cost basis | (80130) | (64051) |
| Total inventories | $221764 | $212386 |

---

Substantially all of the Company's inventories at June 30, 2025 and December 31, 2024 are valued at the lower of cost or market using the last-in, first-out ("LIFO") method. However, approximately 6% was valued at average cost using the first-in, first-out ("FIFO") method at June 30, 2025.

The excess of replacement cost over the carrying value of total inventories subject to LIFO was $75.9 million and $57.5 million at June 30, 2025 and December 31, 2024, respectively.

**7. Leases**

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use assets ("ROU"), Operating lease liabilities – short-term, and Operating lease liabilities – long-term in our Condensed Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment – net, Accounts payable, and Other liabilities in our Condensed Consolidated Balance Sheets.

The components of lease expense were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Finance lease cost: |  |  |  |  |
| &nbsp;&nbsp;Amortization of right-of-use asset | $249 | $264 | $503 | $508 |
| &nbsp;&nbsp;Interest on lease liabilities | 38 | 39 | 79 | 77 |
| &nbsp;&nbsp;Total finance lease cost | 287 | 303 | 582 | 585 |
| Operating lease cost | 13999 | 10797 | 27077 | 22483 |
| Short-term lease cost | 820 | 1141 | 1616 | 2334 |
| Total lease cost | $15106 | $12241 | $29275 | $25402 |

---

As of June 30, 2025, we have no additional operating or finance leases that have not yet commenced.

**8. Goodwill and Intangible Assets**

Intangible assets with finite lives acquired through a business combination are recorded at fair value, less accumulated amortization. Customer relationships and trade-names are amortized on a straight-line basis over their expected useful lives of 15 to 20 years and 5 years, respectively.

*<u>Goodwill</u>*

There was no change in the carrying amount of goodwill for the six months ended June 30, 2025.

*<u>Finite-Lived Intangible Assets</u>*

Intangible assets subject to amortization were as follows:

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Book Value** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Book Value** |
| Customer relationships | $36820 | $(6619) | $30201 | $36820 | $(5666) | $31154 |
| Licenses | 18451 | (7381) | 11070 | 18451 | (6919) | 11532 |
| Trade names | 1100 | (752) | 348 | 1100 | (642) | 458 |
| &nbsp;&nbsp;Total | $56371 | $(14752) | $41619 | $56371 | $(13227) | $43144 |

---

For each of the three months ended June 30, 2025 and June 30, 2024, the Company recorded amortization expense on intangible assets of $0.8 million. For each of the six months ended June 30, 2025 and June 30, 2024, the Company recorded amortization expense on intangible assets of $1.5 million.

**9. Commitments and Contingencies**

The Company is subject to a number of lawsuits, investigations and disputes, some of which may involve substantial amounts claimed, arising out of the conduct of the Company or other third-parties in the normal and ordinary course of business. A liability is recognized for any contingency that is probable of occurrence and reasonably estimable. The Company continually assesses the likelihood of adverse judgments or outcomes in these matters, as well as potential ranges of possible losses, based on an analysis of each matter with the assistance of legal counsel and, if applicable, other experts.

Given the uncertainty inherent in such lawsuits, investigations and disputes, the Company does not believe it is possible to develop estimates of reasonably possible loss in excess of current accruals for these matters. Considering the Company's past experience and existing accruals, the Company does not expect the outcome of these matters, either individually or in the aggregate, to have a material adverse effect on the Company's consolidated financial position or results of operations. Potential liabilities are subject to change due to new developments, changes in settlement strategy or the impact of evidentiary requirements, which could cause the Company to pay damage awards or settlements (or become subject to equitable remedies) that could have a material adverse effect on the Company's consolidated results of operations, balance sheet and/or operating cash flows in the periods recognized or paid.

We assumed from Honeywell International Inc. ("Honeywell") all health, safety and environmental ("HSE") liabilities and compliance obligations related to the past and future operations of our current business, as well as all HSE liabilities associated with our three manufacturing locations and the other locations used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to have a material adverse effect on the Company's consolidated financial position or results of operations.

**10. Income Taxes**

The provision for income taxes was $0.3 million and $13.1 million for the three months ended June 30, 2025 and 2024, respectively, resulting in an effective tax rate of 0.9% and 25.2%, respectively. The provision for income taxes was $5.9 million and $7.1 million for the six months ended June 30, 2025 and 2024, respectively, resulting in an effective tax rate of 9.7% and 24.9%, respectively.

The Company's provision for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The Company's effective tax rate for the three and six months ended June 30, 2025 differed from the U.S. federal statutory rate due to state taxes and executive compensation deduction limitations which generally increase the rate, offset by research tax credits that generally decrease the rate. Additionally, discrete tax adjustments recorded in the first and second quarter of 2025 related to Internal Revenue Code (IRC) Section 45Q tax credits of $1.8 million and $7.9 million, respectively, offset slightly by state tax legislation changes, resulted in a net 24.7% and 15.7% decrease in the rate for the three and six months ended June 30, 2025, respectively. The Company's effective tax rate for the three and six months ended June 30, 2024 was higher than the U.S.

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

federal statutory rate, due to the impacts of state taxes and executive compensation deduction limitations which generally increase the tax rate, partially offset by tax credits which generally decrease the tax rate.

**11. Supplier Finance Programs**

The Company has entered into a supply chain finance program with a financial intermediary providing participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. AdvanSix's responsibility is limited to making payments to the intermediary based upon payment terms negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. The Company's payment terms with suppliers are consistent, regardless of whether a vendor participates in the supply chain finance program or not. All related agreements are terminable by either party upon at least 30 days' notice.

The total amount due to the financial intermediary to settle supplier invoices under its supply chain finance program was approximately $19.8 million as of June 30, 2025 and approximately $19.2 million as of December 31, 2024. These amounts outstanding are included in Accounts payable.

**12. Segment Related Information**

The Company has concluded that it is a single operating segment and a single reportable segment: chemical manufacturing. Its larger manufacturing sites are vertically integrated and leverage cross-plant resources, including centralized supply chain and procurement functions. This production process uses one key raw material, cumene, as the input to products produced for sale through the sales channels and end markets the Company serves. Production rates and output volumes are managed across locations to align with the Company's overall operating plan. Additionally, the Company's operating results, which are evaluated regularly to make decisions about resource allocation and performance assessment by the chief operating decision maker ("CODM"), our CEO and President, are on a consolidated basis.

The chemical manufacturing segment derives its revenues by innovating and delivering essential products in the industries of nylon solutions, plant nutrients, and chemical intermediates to its customers in a wide variety of end markets and applications, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics.

The CODM's performance assessment and resource allocation for the chemical manufacturing segment is based on net income which is also reported on the income statement as net income, the measure of segment assets which is also reported on the balance sheet as total assets, and capital expenditures which is also reported in management's discussion and analysis.

The CODM uses net income generated from segment assets in deciding whether to reinvest profits into the segment or into other parts of the entity, such as for acquisitions or to pay dividends. The CODM also uses net income to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management's compensation. Lastly, the CODM uses capital expenditures to estimate the cash-generating potential and cash requirements of the segment.

Significant expense information reviewed by the CODM was as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue | $410022 | $453479 | $787813 | $790308 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;Variable costs of goods sold \* | 175178 | 204090 | 328082 | 375530 |
| &nbsp;&nbsp;Plant costs | 127376 | 118968 | 249229 | 235399 |
| &nbsp;&nbsp;Freight and distribution costs | 46211 | 46859 | 93614 | 90158 |
| &nbsp;&nbsp;Selling, general, and administrative expense | 25416 | 24431 | 48825 | 48024 |
| &nbsp;&nbsp;Other segment items \*\* | 4470 | 20204 | 13348 | 19666 |
| Segment net income | $31371 | $38927 | $54715 | $21531 |

---

*\*Variable costs of goods sold includes the raw material costs associated with volumes sold during the period as well as insurance settlement proceeds, when applicable.*

*\*\*Other segment items include research and development expense, interest income and expense, capitalized interest, other non-operating expense, and income tax expense.*

**13. Subsequent Events**

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

As announced on August 1, 2025, the Board declared a quarterly cash dividend of $0.16 per share on the Company's common stock, payable on August 26, 2025 to stockholders of record as of the close of business on August 12, 2025.

------

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion and analysis of the Company's financial condition and results of operations, which we refer to as our "MD&A," should be read in conjunction with the Condensed Consolidated Financial Statements and the notes thereto contained in this Quarterly Report on Form 10-Q (this "Form 10-Q"), as well as the MD&A section included in our Annual Report on Form 10-K for the year ended December 31, 2024 ("2024 Form 10-K"). Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a number of factors that can affect our performance in both the near- and long-term, including those incorporated by reference in Item 1A of Part II of this Form 10-Q as such factors may be revised or supplemented in subsequent filings with the SEC, as well as those discussed in the section entitled "Note Regarding Forward-Looking Statements" below.

**Note Regarding Forward-Looking Statements**

All statements other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this MD&A regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements within the meaning of Section 21E of the Exchange Act. When used in this Form 10-Q, words such as "expect," "anticipate," "estimate," "outlook," "project," "strategy," "intend," "plan," "target," "goal," "may," "will," "should," and "believe," and other variations or similar terminology and expressions identify forward-looking statements. Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties and other factors, many of which are beyond our control and difficult to predict, which may cause the actual results or performance of the Company to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: general economic and financial conditions in the U.S. and globally; the potential effects of inflationary pressures, tariffs or the imposition of new tariffs, trade wars, barriers or restrictions, or threats of such actions, changes in interest rates, labor market shortages and supply chain issues; instability or volatility in financial markets or other unfavorable economic or business conditions caused by geopolitical concerns, including as a result of new or proposed legislation or regulatory, trade or other policies in or impacting the U.S., the conflict between Russia and Ukraine, the conflicts in Israel, Gaza and Iran, related uncertainty in the surrounding region, and the possible expansion of such conflicts; the effect of any of the foregoing on our customers' demand for our products and our suppliers' ability to manufacture and deliver our raw materials, including implications of reduced refinery utilization in the U.S.; our ability to sell and provide our goods and services; the ability of our customers to pay for our products; any closures of our and our customers' offices and facilities; risks associated with increased phishing, compromised business emails and other cybersecurity attacks, data privacy incidents and disruptions to our technology infrastructure; risks associated with operating with a reduced workforce; risks associated with our indebtedness including compliance with financial and restrictive covenants, and our ability to access capital on reasonable terms, at a reasonable cost, or at all, due to economic conditions or otherwise; the impact of scheduled turnarounds and significant unplanned downtime and interruptions of production or logistics operations as a result of mechanical issues or other unanticipated events such as fires, severe weather conditions, natural disasters, pandemics and geopolitical conflicts and related events; price fluctuations, cost increases and supply of raw materials; our operations and growth projects requiring substantial capital; growth rates and cyclicality of the industries we serve including global changes in supply and demand; failure to develop and commercialize new products or technologies; loss of significant customer relationships; adverse trade and tax policies; extensive environmental, health and safety laws that apply to our operations; hazards associated with chemical manufacturing, storage and transportation; litigation associated with chemical manufacturing and our business operations generally; inability to acquire and integrate businesses, assets, products or technologies; protection of our intellectual property and proprietary information; prolonged work stoppages as a result of labor difficulties or otherwise; failure to maintain effective internal controls; our ability to declare and pay quarterly cash dividends and the amounts and timing of any future dividends; our ability to repurchase our common stock and the amount and timing of any future repurchases; disruptions in supply chain, transportation and logistics; potential for uncertainty regarding qualification for tax treatment of our spin-off; fluctuations in our stock price; and changes in laws or regulations applicable to our business. Forward-looking statements are not guarantees of future performance and actual results could differ materially from those contemplated by the forward-looking statements as a result of a number of risks, uncertainties and other factors including those noted above and those detailed in Item 1A of Part I and elsewhere in our 2024 Form 10-K, and subsequent reports filed with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We do not undertake to update or revise any of our forward-looking statements.

**Business Overview**

AdvanSix is a diversified chemistry company that produces essential materials for our customers in a wide variety of end markets and applications that touch people's lives. Our integrated value chain of our five U.S.-based manufacturing facilities plays a critical role in global supply chains and enables us to innovate and deliver essential products for our customers across building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, electronics and

------

other end markets. Guided by our core values of Safety, Integrity, Accountability and Respect, AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, plant nutrients, and chemical intermediates. Our key product lines are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;**• Nylon Solutions**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**◦ Nylon –** We sell our Nylon 6 resin globally, primarily under the Aegis® brand name. Nylon 6 is a polymer resin which is a synthetic material used by our customers to produce fibers, filaments, engineered plastics and films that, in turn, are used in such end-products as carpets, automotive and electric components, sports apparel, food packaging and other industrial applications.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ **Caprolactam –** Caprolactam is the key monomer used in the production of Nylon 6 resin. We internally polymerize caprolactam into Aegis® Nylon 6 Resins, and we also market and sell the caprolactam that is not consumed internally to customers who use it to manufacture polymer resins to produce fibers, compounds and other nylon products. Our Hopewell, VA manufacturing facility is one of the world's largest single-site producers of caprolactam as of June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;**• Plant Nutrients –** Our ammonium sulfate is used by customers as a fertilizer containing nitrogen and sulfur, two key plant nutrients. Ammonium sulfate fertilizer is derived from the integrated operations at the Hopewell manufacturing facility. Because of our Hopewell facility's size, scale and technology design, we are the world's largest single-site producer of ammonium sulfate fertilizer as of June 30, 2025. We market and sell ammonium sulfate primarily to North American and South American distributors, farm cooperatives and retailers to fertilize crops. We also manufacture sulfuric acid, ammonia and carbon dioxide as part of our integrated operations at Hopewell and occasionally sell any excess material not consumed internally to customers externally.

&nbsp;&nbsp;&nbsp;&nbsp;**• Chemical Intermediates –** We manufacture, market and sell a number of chemical intermediate products that are derived from the manufacturing processes within our integrated supply chain. Most significant is acetone which is used by our customers in the production of solvents, paints, coatings, adhesives, resins and herbicides. Other intermediate chemicals that we manufacture, market and sell include phenol, alpha-methylstyrene, cyclohexanone, oximes, cyclohexanol, and alkyl and specialty amines. Additional end-products for intermediates include automotive components, and water treatment and pharmaceutical intermediates.

Global demand for Nylon 6 resin spans a variety of end-uses such as textiles, engineered plastics, industrial filament, food and industrial films, and carpet. The market growth typically tracks global GDP growth over the long-term but varies by end-use. We produce and sell caprolactam as a commodity product and produce and sell our Nylon 6 resin as both a commoditized and differentiated resin product. Our results of operations are primarily driven by production volume and the spread between the sales prices of our products and the costs of the underlying raw materials built into market-based and value-based pricing models. The global prices for nylon resin typically track a spread over the price of caprolactam, which in turn tracks as a spread over benzene because the key feedstock materials for caprolactam, phenol or cyclohexane, are derived from benzene. This price spread has historically experienced cyclicality as a result of global changes in supply and demand. Generally, Nylon 6 resin prices track the cyclicality of caprolactam prices, although prices set above the spread are achievable when nylon resin manufacturers, like AdvanSix, formulate and produce differentiated nylon resin products for current and new customer applications, such as our wire and cable and co-polymer offerings.

Global prices for ammonium sulfate fertilizer are influenced by several factors including the price of urea, which is the most widely used source of nitrogen-based fertilizer in the world. Other global factors driving ammonium sulfate fertilizer demand are general agriculture trends, including planted acres and the price of crops. Our ammonium sulfate product is positioned with the added value proposition of sulfur nutrition to increase yields of key crops. In addition, due to its nutrient density, the typical ammonium sulfate product delivers pound for pound the most readily available sulfur and nitrogen to crops as compared to other fertilizers. We also directly supply packaged ammonium sulfate to customers, primarily in North and South America, and have diversified and optimized our offerings to include spray-grade adjuvants to support crop protection, as well as other specialty fertilizers and products for industrial use.

Our ammonium sulfate fertilizer experiences quarterly sales seasonality reflecting both geographical and product sales mix considerations based on the timing and length of the growing seasons in North and South America. The North American fertilizer season typically runs from July, when the value chain begins restocking fertilizer, through June of the following year, when most application for the year's planting is completed. The new season fill begins in the third quarter and proceeds sequentially into the following spring, which is the peak period for crop fertilizer application. As a result of this pattern, North American ammonium sulfate demand and pricing, particularly for our higher-value granular product, are typically strongest in the first half of the year through application for the spring crop and then decline in the second half of the year. Ammonium

------

sulfate industry prices in the corn belt have declined approximately 10% from the second quarter to the third quarter, on average, since 2016. Due to the ammonium sulfate fertilizer sales cycle, we occasionally build up higher inventory balances because our production is continuous throughout the year and not tied to seasonal demand for fertilizers. Sales of most of our other products have generally been subject to minimal, or no, seasonality.

We also manufacture, market and sell a number of chemical intermediate products that are derived from the manufacturing processes within our integrated supply chain. Most significant is acetone, the price of which is influenced by its own supply and demand dynamics but can also be influenced by the underlying move in propylene input costs. Our differentiated product offerings include high-purity applications and high-value intermediates including our U.S. Amines portfolio as well as our oximes-based EZ-Blox™ anti-skinning agent used in paints and Nadone® cyclohexanone, which is a solvent used in various high-value applications.

We seek to run our production facilities on a nearly continuous basis for maximum efficiency as several of our intermediate products are key feedstock materials for other products in our integrated manufacturing chain. While our integration, scale and range of product offerings make us one of the most efficient manufacturers in our industry, these attributes also expose us to increased risk associated with material disruptions at any one of our production facilities or logistics operations which could impact the overall manufacturing supply chain. Further, although we believe that our sources of supply for our raw materials, including cumene, natural gas and sulfur, are generally robust, it is difficult to predict the impact that shortages, increased costs and related supply chain logistics considerations may have in the future. In order to mitigate the risk of unplanned interruptions, we schedule planned plant turnarounds each year to conduct routine and major maintenance across our facilities. We also utilize maintenance excellence and mechanical integrity programs, targeted buffer inventory of intermediate chemicals necessary for our manufacturing process, and co-producer swap arrangements, which are intended to mitigate the extent of any production losses as a result of planned and unplanned downtime; however, the mitigation of all or part of any such production impact cannot be assured.

**Recent Developments**

*<u>Succession of Chief Financial Officer</u>*

As previously reported, effective as of July 9, 2025, the Company's Board of Directors (the "Board") appointed Christopher Gramm as Interim Chief Financial Officer, replacing Siddharth Manjeshwar, whose employment as Senior Vice President and Chief Financial Officer was terminated on July 9, 2025. The Company has commenced a search for a permanent successor.

*<u>Anti-Dumping Duty Petition - Acetone</u>*

On November 4, 2024, the U.S. Department of Commerce ("Commerce") initiated the first five-year review of the anti-dumping orders on imports of acetone from Belgium, Singapore, South Africa, South Korea, and Spain. On November 1, 2024, the U.S. International Trade Commission ("ITC") issued its notice of initiation of its five-year review of the orders. The anti-dumping orders and applicable duties will continue for another five-year period if Commerce finds that revocation of the orders is likely to lead to continuation or recurrence of dumping and if the ITC finds that revocation is likely to lead to continuation or recurrence of material injury to the U.S. domestic industry. On December 26, 2024, Commerce notified the ITC that it would conduct an expedited review and issue its results no later than March 4, 2025. On February 4, 2025, the ITC voted to conduct a full review and is expected to issue its results in the fourth quarter of 2025. On March 7, 2025, Commerce determined that revocation of the anti-dumping orders would likely lead to continuation of recurrence of dumping. The anti-dumping duties will continue to apply during the ITC's pending review.

*<u>Philadelphia Energy Solutions' Shut Down</u>*

The Company previously reported a business impact associated with the June 2019 fire that shut down the Philadelphia Energy Solutions ("PES") refinery in Philadelphia, Pennsylvania. PES was one of multiple suppliers to the Company of cumene, a feedstock material used to produce phenol, acetone and other chemical intermediates. The Company has been actively pursuing the claim over several years, with a final omnibus settlement in January 2025 which resulted in insurance settlement proceeds of approximately $26 million in the first quarter of 2025. The total aggregate insurance proceeds since the original claim submission are approximately $39 million.

**<u>Results of Operations</u>**

(Dollars in thousands, unless otherwise noted)

------

**Sales**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2025** | **2024** | **2025** | **2025** | **2024** |
| Sales | $| 410022 | $453479 | $| 787813 | $790308 |
| % change compared with prior year period | (9.6)% | (9.6)% |  | (0.3)% | (0.3)% |  |

---

The change in sales compared to the prior year period is attributable to the following:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>June 30, 2025** | **Six Months Ended<br>June 30, 2025** |
| Volume | (8.1)% | (1.2)% |
| Price | (1.5)% | 0.9% |
|  | (9.6)% | (0.3)% |

---

Sales decreased in the three months ended June 30, 2025 compared to the prior year period by $43.5 million (approximately 10%) due to (i) decreased volume (approximately 8%) primarily driven by softer demand in key nylon end markets and (ii) lower raw material pass through pricing (approximately 5%) following a net cost decrease in benzene and propylene (inputs to cumene which is a key feedstock to our products), partially offset by favorable market-based pricing (approximately 3%) driven by continued strength in Plant Nutrients reflecting favorable North American ammonium sulfate supply and demand conditions.

Sales were approximately flat in the six months ended June 30, 2025 compared to the prior year period due to decreased volume (approximately 1%) driven by softer demand in key nylon end markets partially offset by higher granular ammonium sulfate sales supported by our SUSTAIN (Sustainable U.S. Sulfate to Accelerate Increased Nutrition) program. This was offset by higher pricing (approximately 1%), primarily reflecting favorable market-based pricing across our Plant Nutrients and Nylon Solutions product lines partially offset by lower raw material pass through pricing following a net cost decrease in benzene and propylene.

**Costs of Goods Sold**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| Costs of goods sold | $| 351308 | $| 372111 | $| 675628 | $| 705975 |
| % change compared with prior year period | (5.6)% | (5.6)% |  |  | (4.3)% | (4.3)% |  |  |
| Gross Margin percentage | 14.3% | 14.3% | 17.9% | 17.9% | 14.2% | 14.2% | 10.7% | 10.7% |

---

Costs of goods sold decreased in the three months ended June 30, 2025 compared to the prior year period by $20.8 million (approximately 6%) due to decreased volume (approximately 9%) driven by lower nylon sales as a result of soft end market demand, partially offset by (i) increased operational costs (approximately 2%) driven by utility spend and (ii) increased raw material costs (approximately 1%) driven by natural gas and sulfur.

Costs of goods sold decreased in the six months ended June 30, 2025 compared to the prior year period by $30.3 million (approximately 4%) due to (i) insurance proceeds collected as a result of the PES supplier shutdown (approximately 4%), (ii) decreased operational costs (approximately 2%) primarily driven by improved operational performance, and (iii) decreased sales volume (approximately 2%), partially offset by increased raw material costs (approximately 3%) driven by natural gas and sulfur.

Gross margin percentage decreased in the three months ended June 30, 2025 compared to the prior year period (approximately 4%) due primarily to (i) increased plant costs (approximately 2%) driven by utility spend and (ii) the impact of market-based pricing, net of raw material costs (approximately 2%).

Gross margin percentage increased by approximately 4% in the six months ended June 30, 2025 compared to the prior year period due to (i) insurance proceeds collected as a result of the PES supplier shutdown (approximately 3%), (ii) decreased plant costs (approximately 1%) primarily driven by improved operational performance, and (iii) the net impact of lower sales volume and change in sales mix (approximately 1%), partially offset by the impact of market-based pricing, net of raw material costs (approximately 2%).

**Selling, General and Administrative Expenses**

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| Selling, general and administrative expenses | $| 25416 | $| 24431 | $| 48825 | $| 48024 |
| Percentage of Sales | 6.2% | 6.2% | 5.4% | 5.4% | 6.2% | 6.2% | 6.1% | 6.1% |

---

Selling, general and administrative expenses increased by $1.0 million in the three months ended June 30, 2025 compared to the prior year period due primarily to the planned investment to upgrade our enterprise resource planning system.

Selling, general and administrative expenses increased by $0.8 million in the six months ended June 30, 2025 compared to the prior period due primarily to the planned investment to upgrade our enterprise resource planning system.

**Income Tax Expense**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| Income tax expense | $| 279 | $| 13145 | $| 5864 | $| 7124 |
| Effective tax rate | 0.9% | 0.9% | 25.2% | 25.2% | 9.7% | 9.7% | 24.9% | 24.9% |

---

The Company's provision for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The Company's effective tax rate for the three and six months ended June 30, 2025 differed from the U.S. federal statutory rate due to state taxes and executive compensation deduction limitations which generally increase the rate, offset by research tax credits that generally decrease the rate. Additionally, discrete tax adjustments recorded in the first and second quarter of the year related to Internal Revenue Code (IRC) Section 45Q tax credits of $1.8 million and $7.9 million, respectively, offset slightly by state tax legislation resulted in a net 24.7% and 15.7% decrease in the rate for the three and six months ended June 30, 2025, respectively. The Company's effective tax rate for the three and six months ended June 30, 2024 was higher than the U.S. federal statutory rate, due to the impacts of state taxes and executive compensation deduction limitations which generally increase the tax rate, partially offset by tax credits which generally decrease the tax rate.

The Company's effective tax rate for the three and six months ended June 30, 2025 was lower than the prior year period due primarily to the impact of the IRC Section 45Q tax credits recorded in the first half of the current year compared to the first half of the prior year.

On July 4, 2025, President Trump signed into law legislation commonly referred to as the One Big Beautiful Bill Act (the "Act"), which includes numerous tax reform provisions affecting businesses, including extending and modifying certain provisions of the Tax Cuts and Jobs Act (both domestic and international), while also introducing major changes to federal energy policy by rolling back many clean energy provisions enacted as part of the Inflation Reduction Act. The Act includes a broad array of business-related provisions, including the full expensing of domestic research and experimental expenditures (i.e., R&D costs), modification of the limitation on business interest and making permanent full expensing for certain business property (i.e., 100 percent bonus depreciation). While we do not currently anticipate that the clean energy provisions will have a material impact on our financial results, we continue to evaluate these provisions. However, we do anticipate that the changes to R&D costs and the 100 percent bonus deprecation provisions will result in lower cash taxes in future periods. Due to the elective applicability of these provisions, we are still in the process of modeling and performing a full evaluation before determining the full impact and timing that these provisions will have on our financial results. Since the Act was enacted after the June 30 period-end date, no provisions are accounted for in our current financial statements. Due to the variety of effective dates for key provisions, we anticipate only certain provisions will impact our third and fourth quarter financial statements but the Company is unable to reasonably estimate the full impact of the Act on its financial statements at this time.

**Net Income**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income | $31371 | $38927 | $54715 | $21531 |

---

As a result of the factors described above, Net income was $31.4 million and $54.7 million for the three and six months ended June 30, 2025, respectively, as compared to $38.9 million and $21.5 million in the corresponding prior year period.

**<u>Non-GAAP Measures</u>**

(Dollars in thousands, unless otherwise noted)

The following tables set forth the non-GAAP financial measures of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net income and Adjusted EPS. Adjusted EBITDA is defined as Net income before Interest, Income taxes, Depreciation and amortization, Non-cash stock-based compensation, Non-recurring, unusual or extraordinary expenses, Non-cash amortization from acquisitions and One-time merger and acquisition costs. Adjusted EBITDA Margin is equal to Adjusted EBITDA divided by Sales. The Company believes these non-GAAP financial measures provide meaningful supplemental information as they are used by the Company's management to evaluate the Company's operating performance, enhance a reader's understanding of the financial performance of the Company, and facilitate a better comparison among fiscal periods and performance relative to its competitors, as the non-GAAP measures exclude items that management believes do not reflect the Company's ongoing operations.

These non-GAAP results are presented for supplemental informational purposes only and should not be considered a substitute for the financial information presented in accordance with U.S. GAAP. Non-GAAP financial measures should be read only in conjunction with the comparable U.S. GAAP financial measures. The Company's non-GAAP measures may not be comparable to other companies' non-GAAP measures.

The following is a reconciliation between the non-GAAP financial measures of Adjusted Net income, Adjusted EBITDA and Adjusted EBITDA Margin to their most directly comparable U.S. GAAP financial measure:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2025** | **2024** | **2025** | **2024** |
| Net income | $| 31371 | 38927 | 54715 | 21531 |
| Non-cash stock-based compensation | 2309 | 2309 | 2193 | 4287 | 4404 |
| Non-recurring, unusual or extraordinary expense\* |  |  | 1200 |  | 1200 |
| Non-cash amortization from acquisitions | 531 | 531 | 532 | 1063 | 1064 |
| Non-recurring M&A costs |  |  |  |  |  |
| Income tax benefit relating to reconciling items | (479) | (479) | (762) | (909) | (1227) |
| Adjusted Net income (non-GAAP) | 33732 | 33732 | 42090 | 59156 | 26972 |
| Interest expense, net | 2255 | 2255 | 3514 | 3796 | 6213 |
| Income tax expense - Adjusted | 758 | 758 | 13907 | 6773 | 8351 |
| Depreciation and amortization - Adjusted | 18930 | 18930 | 18630 | 37576 | 37200 |
| Adjusted EBITDA (non-GAAP) | $| 55675 | 78141 | 107301 | 78736 |
| Sales | $| 410022 | 453479 | 787813 | 790308 |
| Adjusted EBITDA Margin\*\* (non-GAAP) | 13.6% | 13.6% | 17.2% | 13.6% | 10.0% |

---

*\* 2024 includes a pre-tax loss of approximately $1.2 million from the reduction of the Company's anticipated receivable related to the gain on the termination fee recorded upon the exit from the Oben Holding Group S.A. alliance during the third quarter of 2023.*

*\*\* Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Sales.*

The following is a reconciliation between the non-GAAP financial measures of Adjusted EPS to its most directly comparable U.S. GAAP financial measure:

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income | $31371 | $38927 | $54715 | $21531 |
| Adjusted Net income (non-GAAP) | 33732 | 42090 | 59156 | 26972 |
| Weighted-average number of common shares outstanding - basic | 26896037 | 26839429 | 26867252 | 26859044 |
| Dilutive effect of equity awards and other stock-based holdings | 327272 | 310918 | 381724 | 392282 |
| Weighted-average number of common shares outstanding - diluted | 27223309 | 27150347 | 27248976 | 27251326 |
| EPS - Basic | $1.17 | $1.45 | $2.04 | $0.80 |
| EPS - Diluted | $1.15 | $1.43 | $2.01 | $0.79 |
| Adjusted EPS - Basic (non-GAAP) | $1.25 | $1.57 | $2.20 | $1.00 |
| Adjusted EPS - Diluted (non-GAAP) | $1.24 | $1.55 | $2.17 | $0.99 |

---

**<u>Liquidity and Capital Resources</u>**

(Dollars in thousands, unless otherwise noted)

**Liquidity**

We believe that cash balances and operating cash flows, together with available capacity under our credit agreement, as utilized in the second quarter of 2025, will provide adequate funds to support our current short-term operating objectives as well as our longer-term strategic plans, subject to the risks and uncertainties outlined below, in our "Note Regarding Forward-Looking Statements" above, and in the risk factors previously disclosed in Item 1A of Part I of our 2024 Form 10-K. Our principal source of liquidity is our cash flow generated from operating activities, which is expected to provide us with the ability to meet the majority of our short-term funding requirements for the next twelve months and beyond. Our cash flows are affected by capital requirements and production volume, which may be materially impacted by unanticipated events such as unplanned downtime, material disruptions at our production facilities, the prices of our raw materials, general economic and industry trends and customer demand. The Company applies a proactive and disciplined approach to working capital management to optimize cash flow and to enable capital allocation options in support of the Company's strategy. We utilize supply chain financing and trade receivables discount arrangements with third-party financial institutions which optimize terms and conditions related to accounts receivable and accounts payable in order to enhance liquidity and enable us to efficiently manage our working capital needs. Although we continue to optimize supply chain financing and trade receivable programs in the ordinary course, our utilization of these arrangements has not had a material impact on our liquidity. In addition, we monitor the third-party depository institutions that hold our cash and cash equivalents. Our emphasis is primarily on the safety of principal and secondarily on maximizing yield on those funds. We diversify our cash and cash equivalents among counterparties to minimize exposure to any one of these entities.

On a recurring basis, our primary future cash needs will be centered on operating activities, working capital, capital expenditures, dividends and liquidity reflecting disciplined capital deployment. Capital expenditures are deployed for various ongoing investments and initiatives to improve reliability, yield and quality, expand production capacity and comply with health, safety and environmental ("HSE") regulations. We believe that our future cash from operations, cash on hand and available capacity under our credit agreement, as well as our access to credit and capital markets, will provide adequate resources to fund our expected operating and financing needs and obligations. Our ability to fund our capital needs, however, will depend on our ongoing ability to generate cash from operations and access to credit and capital markets, both of which are subject to the risk factors previously disclosed in Item 1A of Part I of our 2024 Form 10-K, as well as general economic, financial, competitive, regulatory and other factors that are beyond our control.

As of the end of the second quarter of 2025, the Company had approximately $18.4 million of cash on hand with approximately $259 million of additional capacity available under the revolving credit facility. The Company's Consolidated Leverage Ratio financial covenant of its credit facility allows it to net up to $75 million of cash with debt. Capital expenditures are expected to

------

be approximately $135 million to $145 million in 2025 compared to $134 million in 2024, reflecting the planned progression of our SUSTAIN growth program, and refined execution timing to address critical enterprise risk mitigation.

We assumed from Honeywell International Inc. ("Honeywell") all HSE liabilities and compliance obligations related to the past and future operations of our current business as of the spin-off, as well as all HSE liabilities associated with the three manufacturing locations assumed from Honeywell that are used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to have a material adverse effect on the Company's consolidated financial position or results of operations.

We expect that our primary cash requirements for 2025 will be to fund costs associated with ongoing operations, capital expenditures, and amounts related to other contractual obligations.

The Company made no cash contributions to the defined benefit pension plan during the six months ended June 30, 2025 as there were no funding requirements for the period. Additional contributions may be made in future periods sufficient to satisfy pension funding requirements in those periods or on a discretionary basis.

On February 17, 2023, the Board authorized a share repurchase program to repurchase shares of the Company's common stock. As of June 30, 2025, the Company has repurchased a total of 6,308,099 shares of common stock life-to-date, including 1,062,643 shares withheld to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $194.0 million at a weighted average market price of $30.75 per share. As of June 30, 2025, approximately $62.0 million remained available for share repurchases under the currently authorized repurchase program. During the period July 1, 2025 through July 25, 2025, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Exchange Act, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.

As of June 30, 2025, the Company did not have any off-balance sheet arrangements as described in Instruction 8 to Item 303(b) of Regulation S-K and did not have any material changes in the commitments or contractual obligations detailed in the 2024 Form 10-K (see Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" under "Liquidity and Capital Resources - Liquidity"). The Company has not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.

*<u>Dividends</u>*

The Company commenced the declaration of dividends on September 28, 2021.

Dividends paid during 2025 and the dividend announced on the date of this filing are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Date of Announcement** | **Date of Record** | **Date Payable** | **Dividend per Share** | **Total Approximate Dividend Amount ($M)** |
| 8/1/2025 | 8/12/2025 | 8/26/2025 | $0.16 | $4.3 |
| 5/2/2025 | 5/13/2025 | 5/27/2025 | $0.16 | $4.3 |
| 2/21/2025 | 3/10/2025 | 3/24/2025 | $0.16 | $4.3 |

---

The timing, declaration, amount and payment of future dividends to stockholders, if any, will fall within the discretion of our Board. Holders of shares of our common stock will be entitled to receive dividends when, and if, declared by our Board at its discretion out of funds legally available for that purpose, subject to the terms of our indebtedness, the preferential rights of any

------

preferred stock that may be outstanding, legal requirements, regulatory constraints, industry practice and other factors that our Board deems relevant.

**Credit Agreement**

On October 27, 2021, the Company entered into a Credit Agreement (the "Credit Agreement"), among the Company, the lenders party thereto, the swing line lenders party thereto, the letter of credit issuers party thereto and Truist Bank, as administrative agent, which provides for a senior secured revolving credit facility in an aggregate principal amount of $500 million (the "Revolving Credit Facility").

Borrowings under the Revolving Credit Facility are subject to customary borrowing conditions.

The Revolving Credit Facility has a scheduled maturity date of October 27, 2026, which the Company expects to refinance before such date. The Credit Agreement permits the Company to utilize up to $40 million of the Revolving Credit Facility for the issuance of letters of credit and up to $40 million for swing line loans. The Company has the option to establish a new class of term loans and/or increase the amount of the Revolving Credit Facility in an aggregate principal amount for all such incremental term loans and increases of the Revolving Credit Facility of up to the sum of (x) $175 million plus (y) an amount such that the Company's Consolidated First Lien Secured Leverage Ratio (as defined in the Credit Agreement) would not be greater than 2.75 to 1.00, in each case, to the extent that any one or more lenders, whether or not currently party to the Credit Agreement, commits to be a lender for such amount or any portion thereof.

Borrowings under the Credit Agreement bear interest at a rate equal to either the sum of a base rate plus a margin ranging from 0.25% to 1.25% or the sum of an Adjusted Term SOFR rate plus a margin ranging from 1.25% to 2.25%, with either such margin varying according to the Company's Consolidated Leverage Ratio (as defined in the Credit Agreement). The Company is also required to pay a commitment fee in respect of unused commitments under the Revolving Credit Facility, if any, at a rate ranging from 0.15% to 0.35% per annum depending on the Company's Consolidated Leverage Ratio.

Substantially all tangible and intangible assets of the Company and its domestic subsidiaries are pledged as collateral to secure the Company's obligations under the Credit Agreement.

The Credit Agreement contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, pay cash dividends, incur debt or liens, redeem or repurchase stock of the Company, enter into transactions with affiliates, make investments, make capital expenditures, merge or consolidate with others or dispose of assets. The Credit Agreement also contains financial covenants that require the Company to maintain a Consolidated Interest Coverage Ratio (as defined in the Credit Agreement) of not less than 3.00 to 1.00 and to maintain a Consolidated Leverage Ratio of 3.75 to 1.00 or less (subject to the Company's option to elect a consolidated leverage ratio increase in connection with certain acquisitions). If the Company does not comply with the covenants in the Credit Agreement, the lenders may, subject to customary cure rights, require the immediate payment of all amounts outstanding under the Revolving Credit Facility. We were in compliance with all of our covenants at June 30, 2025 and through the date of the filing of this Form 10-Q.

We had a borrowed balance of $195 million under the Revolving Credit Facility at December 31, 2024. We borrowed an incremental net amount of $45 million during the six months ended June 30, 2025, bringing the balance under the Revolving Credit Facility to $240 million, and available credit for use of approximately $259 million as of June 30, 2025. We expect that Cash provided by operating activities will fund future interest payments on the Company's outstanding indebtedness.

**Cash Flow Summary**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** |
| Cash provided by (used for): |  |  |
| &nbsp;&nbsp;Operating activities | $32553 | $13998 |
| &nbsp;&nbsp;Investing activities | (68218) | (72619) |
| &nbsp;&nbsp;Financing activities | 34547 | 40958 |
| Net change in cash and cash equivalents | $(1118) | $(17663) |

---

Cash provided by operating activities increased by $18.6 million for the six months ended June 30, 2025 versus the prior year period due primarily to a $33.2 million increase in net income, partially offset by (i) the unfavorable cash impact of $9.6 million from Taxes receivable and Income taxes payable combined, driven by the timing of tax payments and (ii) a $5.6 million

------

unfavorable cash impact from Accrued liabilities due primarily to the timing of payments and accruals during the six months ended June 30, 2025 compared to the prior year period.

Cash used for investing activities decreased by $4.4 million for the six months ended June 30, 2025 versus the prior year period due primarily to the timing of cash payments for capital expenditures and other enterprise programs.

Cash provided by financing activities decreased by $6.4 million for the six months ended June 30, 2025 versus the prior year period due primarily to net borrowings of $45.0 million during the six months ended June 30, 2025 compared to net borrowings of $60.0 million during the prior year period, partially offset by payments for share repurchases of $1.5 million during the six months ended June 30, 2025 compared to $10.4 million during the prior year period.

**<u>Capital Expenditures</u>**

(Dollars in thousands, unless otherwise noted)

Our operations are capital intensive, requiring ongoing investments that have consisted, and are expected to continue to consist, primarily of capital expenditures required to maintain and improve equipment reliability, expand production output, further improve mix, yield and cost position, and comply with environmental and safety regulations.

The following table summarizes ongoing and expansion capital expenditures:

---

| | |
|:---|:---|
| | **Six Months Ended<br>June 30, 2025** |
| Capital expenditures in Accounts payable at December 31, 2024 | $23645 |
| Purchases of property, plant and equipment | 53444 |
| Less: Capital expenditures in Accounts payable at June 30, 2025 | (14762) |
| Cash paid for capital expenditures | $62327 |

---

For 2025, we expect our total capital expenditures to be approximately $135 million to $145 million as discussed above.

**<u>Critical Accounting Policies and Estimates</u>**

The preparation of our Condensed Consolidated Financial Statements in accordance with U.S. GAAP is based on the selection and application of accounting policies that require us to make significant estimates and assumptions about the effects of matters that are inherently uncertain. We consider these accounting policies to be critical to the understanding of our Condensed Consolidated Financial Statements. For a full description of our critical accounting policies, refer to Management's Discussion and Analysis of Financial Condition and Results of Operations contained in our 2024 Form 10-K. While there have been no material changes to our critical accounting policies, or the methodologies or assumptions we apply under them since the filing of the 2024 Form 10-K, we continue to monitor such methodologies and assumptions.

**<u>Recent Accounting Pronouncements</u>**

See "Note 2. Recent Accounting Pronouncements" to the Condensed Consolidated Financial Statements included in Part I. Item 1 of this Form 10-Q.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

**Interest Rate Risk**

Our exposure to risk based on changes in interest rates during the six-month period ended June 30, 2025 relates primarily to the Revolving Credit Facility. The Revolving Credit Facility bears interest at floating rates. For variable rate debt, interest rate changes generally do not affect the fair market value of such debt assuming all other factors remain constant but do impact future earnings and cash flows. Accordingly, we may be exposed to interest rate risk on borrowings under the Credit Agreement.

Based on current borrowing levels at June 30, 2025, a 25-basis point fluctuation in interest rates for the six months ended June 30, 2025 would have resulted in an increase or decrease to our interest expense of approximately $0.6 million.

------

See "Note 2. Summary of Significant Accounting Policies" to the Consolidated Financial Statements included in Item 8 of our 2024 Form 10-K for a discussion relating to credit and market, commodity price and interest rate risk management.

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

The Company maintains disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to management, including the Chief Executive Officer and Interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud have been, or will be, detected.

Our Chief Executive Officer and Interim Chief Financial Officer, with the assistance of other members of our management, conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based upon such evaluation, our Chief Executive Officer and Interim Chief Financial Officer have concluded that our disclosure controls and procedures are effective at a reasonable assurance level as of June 30, 2025, the end of the period covered by this quarterly report.

**Changes in Internal Control over Financial Reporting**

Management has not identified any change in the Company's internal control over financial reporting that occurred during the quarter ended June 30, 2025 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

During the third quarter of 2025, the Company is upgrading its enterprise resource planning ("ERP") system which will replace existing operating and financial systems. The new ERP system is designed to provide enhanced transactional processing, reporting, security and management tools. As the implementation progresses, the Company will continue to evaluate its control processes and will give appropriate consideration to whether any modifications are needed to maintain the effectiveness of its internal controls over financial reporting.

**PART II. OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

From time to time, we are involved in litigation relating to claims arising outside of the ordinary course of our business operations. We are not a party to, and, to our knowledge, there are no pending claims or actions against us, the ultimate disposition of which could be expected to have a material adverse effect on our consolidated financial position, results of operations or operating cash flows.

**ITEM 1A. RISK FACTORS**

There have been no material changes to our risk factors as previously disclosed in Item 1A of Part I of the 2024 Form 10-K, which are hereby incorporated by reference.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

On May 4, 2018, the Company announced that the Board authorized a share repurchase program of up to $75 million of the Company's common stock. On February 22, 2019, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity authorized under the May 2018 share repurchase program. On February 17, 2023, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity available under the previously approved share repurchase program. Repurchases may be

------

made from time to time on the open market in accordance with Rule 10b-18 of the Exchange Act, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The repurchase program has no expiration date and may be modified, suspended or discontinued at any time.

The below table sets forth the repurchases of Company common stock, by month, for the quarter ended June 30, 2025. During the quarter ended June 30, 2025, no additional shares were purchased under our share repurchase program and 2,538 shares were withheld to cover tax withholding obligations in connection with the vesting of equity awards.

**ISSUER PURCHASES OF EQUITY SECURITIES**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Period** | | **Total Number of Shares Purchased** | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Plan** | **Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan** |
| April 2025 | (1) | 2538 | $20.05 |  | $61957898 |
| May 2025 |  |  |  |  | 61957898 |
| June 2025 |  |  |  |  | 61957898 |
| Total |  | 2538 | $20.05 |  |  |

---

(1) Total number of shares purchased includes 2,538 shares covering tax withholding obligations in connection with the vesting of equity awards

During the period July 1, 2025 through July 25, 2025, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

**ITEM 5. OTHER INFORMATION**

**Insider Rule 10b5-1 Trading Plans**

During the quarter ended June 30, 2025, none of our directors or executive officers adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" as those terms are defined in Item 408 of Regulation S-K.

------

**ITEM 6. EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 3.1 | <u>[Amended and Restated Certificate of Incorporation of AdvanSix Inc.](exhibit31_conformedarcerti.htm)[(conformed copy)](exhibit31_conformedarcerti.htm)</u> |
| 3.2 | <u>[Amended and Restated By-laws of AdvanSix Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 20, 2023).](https://www.sec.gov/Archives/edgar/data/1673985/000167398523000091/exhibit31amendedandrestate.htm)</u> |
| 10.1 | <u>[2016 Stock Incentive Plan of AdvanSix Inc. and its Affiliates, as Amended and Restated (effective June 18, 2025) (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed](https://www.sec.gov/Archives/edgar/data/1673985/000167398525000082/stockincentiveplanjune1820.htm)[on June 20, 2025)](https://www.sec.gov/Archives/edgar/data/1673985/000167398525000082/stockincentiveplanjune1820.htm)</u> |
| 31.1 | <u>[Rule 13a-14(a)/15d-14(a) Certification of the Company's Principal Executive Officer.](a10q2025exhibit311ceo.htm)</u> |
| 31.2 | <u>[Rule 13a-14(a)/15d-14(a) Certification of the Company's Principal Financial Officer.](a10q2025exhibit312cfo.htm)</u> |
| 32.1 | <u>[Section 1350 Certification of the Company's Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.](a10q2025exhibit321ceosox.htm)</u> |
| 32.2 | <u>[Section 1350 Certification of the Company's Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.](a10q2025exhibit322cfosox.htm)</u> |
| 101.INS | Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | ADVANSIX INC. | ADVANSIX INC. |
| Date: August 1, 2025 | By: | /s/ Christopher Gramm |
|  |  | **Christopher Gramm** |
|  |  | **Vice President and Interim Chief Financial Officer** |

---

## Exhibit 3.1

**Exhibit 3.1**

**AMENDED AND RESTATED**

**CERTIFICATE OF INCORPORATION**

**OF**

**ADVANSIX INC.**

**(Effective as of June 18, 2025)**

ARTICLE I

The name of the corporation (hereinafter called the "<u>Corporation</u>") is AdvanSix Inc.

ARTICLE II

The address of the Corporation's registered office in the State of Delaware is 2711 Centerville Road, Suite 400, New Castle County, Wilmington, Delaware 19808. The name of the Corporation's registered agent at such address is Corporation Service Company.

ARTICLE III

The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.

ARTICLE IV

SECTION 1. The total number of shares of all classes of stock which the Corporation shall have authority to issue is 250,000,000 shares, consisting of (1) 50,000,000 shares of Preferred Stock, par value $0.01 per share ("<u>Preferred Stock</u>"), and (2) 200,000,000 shares of Common Stock, par value $0.01 per share ("<u>Common Stock</u>"). The number of authorized shares of either the Preferred Stock or the Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Corporation entitled to vote thereon irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware (or any successor provision thereto), and no vote of the holders of either the Preferred Stock or the Common Stock voting separately as a class shall be required therefor.

SECTION 2. The Board of Directors of the Corporation (the "<u>Board of Directors</u>") is hereby expressly authorized, by resolution or resolutions, to provide, out of the unissued shares of Preferred Stock, for series of Preferred Stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of such series, the voting powers (if any) of the shares of such series, and the preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series. The powers, preferences and relative, participating, optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.

SECTION 3. (a) Each holder of Common Stock, as such, shall be entitled to one vote for each share of Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote; <u>provided</u>, <u>however</u>, that, except as otherwise required

------

by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Amended and Restated Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Amended and Restated Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock) or pursuant to the General Corporation Law of the State of Delaware.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as otherwise required by law, holders of a series of Preferred Stock, as such, shall be entitled only to such voting rights, if any, as shall expressly be granted to such holders by this Amended and Restated Certificate of Incorporation (including any Certificate of Designation relating to such series).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Subject to applicable law and the rights, if any, of the holders of any outstanding series of Preferred Stock, dividends may be declared and paid on the Common Stock at such times and in such amounts as the Board of Directors in its discretion shall determine.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Upon the dissolution, liquidation or winding up of the Corporation, subject to the rights, if any, of the holders of any outstanding series of Preferred Stock, the holders of the Common Stock, as such, shall be entitled to receive the assets of the Corporation available for distribution to its stockholders ratably in proportion to the number of shares held by them.

ARTICLE V

SECTION 1. (a) The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. Except as otherwise fixed pursuant to the terms of any outstanding series of Preferred Stock pursuant to this Amended and Restated Certificate of Incorporation (including any Certificate of Designation relating to such series of Preferred Stock), the number of directors of the Corporation shall be fixed from time to time by the Board of Directors. In no event shall a decrease in the number of directors constituting the Board of Directors shorten the term of any incumbent director.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The directors, other than those who may be elected by the holders of any series of Preferred Stock voting separately pursuant to this Amended and Restated Certificate of Incorporation (including any Certificate of Designation relating to such series of Preferred Stock), shall be elected by the stockholders entitled to vote thereon at each annual meeting of the stockholders. From the effective date of this Amended and Restated Certificate of Incorporation until the election of the directors at the 2020 annual meeting of stockholders, the directors of the Corporation shall be divided into three classes, designated Class I, Class II and Class III. Each class shall consist, as nearly as may be possible, of one-third of the total number of directors constituting the entire Board of Directors. If the number of directors has changed, any increase or decrease shall be apportioned among the classes so as to maintain the number of directors in each class as nearly equal as possible, and any additional director of any class elected to fill a vacancy resulting from an increase in such class shall hold office for a term that shall coincide with the remaining term of that class. The initial assignment of directors to each such class shall be made by the Board of Directors. The term of office of the initial Class I directors shall expire at the 2017 annual meeting of stockholders, the term of office of the initial Class II directors shall expire at the 2018 annual meeting of stockholders and the term of office of the initial Class III directors shall expire at the 2019 annual meeting of stockholders. Each director elected at the 2017, 2018 or 2019 annual meeting of stockholders shall belong to the same class as the director whose term shall have then expired and who is being succeeded by such director. Each Class I director elected at the 2017 annual meeting of stockholders, each Class II director elected at the 2018 annual meeting of stockholders and each Class III director elected at the 2019 annual

&nbsp;&nbsp;&nbsp;&nbsp;2

------

meeting of stockholders shall hold office until the 2020 annual meeting of stockholders and, in each case, until his or her respective successor shall have been duly elected and qualified or until his or her earlier resignation or removal. Commencing with the 2020 annual meeting of stockholders, each director shall be elected annually and shall hold office until the next annual meeting of stockholders and until his or her respective successor shall have been duly elected and qualified or until his or her earlier resignation or removal. Pursuant to such procedures, effective as of the conclusion of the 2020 annual meeting of stockholders, the Board of Directors will no longer be classified under Section 141(d) of the General Corporation Law of the State of Delaware and directors shall no longer be divided into three classes. The election of directors need not be by written ballot.

SECTION 2. Advance notice of nominations for the election of directors shall be given in the manner and to the extent provided in the By-laws of the Corporation.

SECTION 3. (a) Except as otherwise provided for or fixed by or pursuant to the provisions of this Amended and Restated Certificate of Incorporation relating to the rights of the holders of any outstanding series of Preferred Stock (including any Certificate of Designation relating to such series of Preferred Stock), newly created directorships resulting from any increase in the number of directors and any vacancies on the Board of Directors resulting from death, resignation, removal or other cause shall only be filled by the Board of Directors by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director, or if not so filled, by the stockholders at the next annual meeting thereof. Any director elected in accordance with the first sentence of this Section 3 shall hold office for a term that shall coincide with the remaining term of the class such director is elected to and until such director's successor shall have been duly elected and qualified or until his or her earlier resignation or removal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) From the effective date of this Amended and Restated Certificate of Incorporation until the election of directors at the 2020 annual meeting of stockholders, any director or the entire Board of Directors may only be removed for cause, such removal to require the affirmative vote of shares representing at least a majority of the votes entitled to be cast by the then outstanding shares of all classes and series of capital stock of the Corporation entitled generally to vote on the election of directors of the Corporation. From and after the 2020 annual meeting of stockholders, any director or the entire Board of Directors may be removed with or without cause, and, in either case, such removal shall require the affirmative vote of shares representing at least a majority of the votes entitled to be cast by the then outstanding shares of all classes and series of capital stock of the Corporation entitled generally to vote on the election of directors of the Corporation. Notwithstanding the foregoing, whenever holders of outstanding shares of one or more series of Preferred Stock voting separately are entitled to elect directors of the Corporation pursuant to the provisions of this Amended and Restated Certificate of Incorporation (including any Certificate of Designation relating to such series of Preferred Stock), any such director of the Corporation so elected may be removed in accordance with this Amended and Restated Certificate of Incorporation (including such Certificate of Designation).

ARTICLE VI

Subject to the rights of the holders of any outstanding series of Preferred Stock, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders. Except as otherwise required by law and subject to the rights of the holders of any outstanding series of Preferred Stock, special meetings of stockholders of the Corporation may be called only by the Board of Directors

&nbsp;&nbsp;&nbsp;&nbsp;3

------

pursuant to a resolution approved by a majority of the entire Board of Directors or as otherwise provided in the By-laws of the Corporation.

ARTICLE VII

In furtherance and not in limitation of the powers conferred upon it by law, the Board of Directors is expressly authorized to adopt, repeal, alter or amend the By-laws of the Corporation by the vote of a majority of the entire Board of Directors. From the effective date of this Amended and Restated Certificate of Incorporation until the election of the directors at the 2020 annual meeting of stockholders, in addition to any requirements of law and any other provision of this Amended and Restated Certificate of Incorporation (and notwithstanding the fact that a lesser percentage may be specified by law), the affirmative vote of the holders of at least 66 2/3% of the combined voting power of the then outstanding shares of all classes and series of capital stock of the Corporation entitled generally to vote in the election of directors of the Corporation, voting together as a single class, shall be required for stockholders to adopt, amend, alter or repeal any provision of the By-laws of the Corporation. Commencing with the 2020 annual meeting of stockholders, in addition to any requirements of law and any other provision of this Amended and Restated Certificate of Incorporation (and notwithstanding the fact that a lesser percentage may be specified by law), the affirmative vote of the holders of at least a majority of the combined voting power of the then outstanding shares of all classes and series of capital stock of the Corporation entitled generally to vote in the election of directors of the Corporation, voting together as a single class, shall be required for stockholders to adopt, amend, alter or repeal any provision of the By-laws of the Corporation.

ARTICLE VIII

The Corporation reserves the right to amend, alter or repeal any provision contained in this Amended and Restated Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon stockholders herein are subject to this reservation.

ARTICLE IX

SECTION 1. To the fullest extent that the General Corporation Law of the State of Delaware or any other law of the State of Delaware as it exists or as it may hereafter be amended permits the limitation or elimination of the liability of directors or officers, no director or officer of the Corporation shall be liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer.

SECTION 2. To the fullest extent that the General Corporation Law of the State of Delaware or any other law of the State of Delaware as it exists or as it may hereafter be amended permits, the Corporation may provide indemnification of (and advancement of expenses to) its current and former directors, officers and agents (and any other persons to which the General Corporation Law of the State of Delaware permits the Corporation to provide indemnification) through By-law provisions, agreements with such agents or other persons, votes of stockholders or disinterested directors or otherwise.

SECTION 3. No amendment to or repeal of any Section of this Article IX, nor the adoption of any provision of this Amended and Restated Certificate of Incorporation inconsistent with this Article IX, shall eliminate or reduce the effect of this Article IX in respect of any matter occurring, or any action or proceeding accruing or arising, prior to such amendment, repeal or adoption of an inconsistent provision.

&nbsp;&nbsp;&nbsp;&nbsp;4

------

ARTICLE X

Unless the Corporation consents in writing to the selection of an alternative forum, the sole and exclusive forum for (a) any derivative action or proceeding brought on behalf of the Corporation, (b) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee or stockholder of the Corporation to the Corporation or the Corporation's stockholders, (c) any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware (or any successor provision thereto) or as to which the General Corporation Law of the State of Delaware (or any successor provision thereto) confers jurisdiction on the Court of Chancery of the State of Delaware or (d) any action asserting a claim governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware or, if the Court of Chancery of the State of Delaware does not have jurisdiction, any other state or federal court located within the State of Delaware. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article X.

&nbsp;&nbsp;&nbsp;&nbsp;5

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATIONS**

I, Erin N. Kane, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of AdvanSix Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 1, 2025

---

| |
|:---|
| /s/ Erin N. Kane |
| Erin N. Kane |
| President and Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATIONS**

I, Christopher Gramm, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of AdvanSix Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 1, 2025

---

| |
|:---|
| /s/ Christopher Gramm |
| Christopher Gramm |
| Vice President and Interim Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of AdvanSix Inc. (the "Company") on Form 10-Q for the period ended June 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge:

1.&nbsp;&nbsp;&nbsp;&nbsp;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: &nbsp;&nbsp;&nbsp;&nbsp;August 1, 2025

---

| |
|:---|
| /s/ Erin N. Kane |
| Erin N. Kane |
| President and Chief Executive Officer |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of AdvanSix Inc. (the "Company") on Form 10-Q for the period ended June 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.&nbsp;&nbsp;&nbsp;&nbsp;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:&nbsp;&nbsp;&nbsp;&nbsp;August 1, 2025

---

| |
|:---|
| /s/ Christopher Gramm |
| Christopher Gramm |
| Vice President and Interim Chief Financial Officer |

---

<br>